Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-ethyl-N-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide
- Development stage
- Preclinical
- Lead developer
- Florida Agricultural and Mechanical University
- Modality
- Small Molecules
01
Overview
4-ethyl-N-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide (also known as GM-3-121) is a synthetic tetrahydroisoquinoline (THIQ) derivative developed by researchers at Florida A&M University. It was designed as an anti-angiogenic and anti-cancer agent. GM-3-121 has demonstrated potent anti-proliferative activity against breast cancer cell lines (including MCF-7 and triple-negative MDA-MB-231) and endometrial adenocarcinoma (Ishikawa) cells. It acts as a cytostatic agent that halts cell cycle progression at the G2/M phase by holding the microtubule network static and preventing mitosis, without functioning as a spindle poison. Additionally, GM-3-121 exhibits anti-angiogenic properties, inhibiting the formation of new blood vessels by targeting the VEGF pathway, and has shown activity as a KRas inhibitor in colorectal cancer models.
- Other names
- 4-ethyl-N-(3,4-dihydroisoquinolin-2(1H)-yl) benzamide
02
Targets
TUBB (Tubulin (alpha and beta subunits))KRAS (Kirsten rat sarcoma viral oncogene homolog)VEGFR (VEGFR family)
Beyond the preview
Go deeper on 4-ethyl-N-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-ethyl-N-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide.